Skin adverse events (AE) such as rash and pruritus are thought to be an on-target, off-tumor TRAE resulting from T-cell redirection to skin melanocytes that also express gp100, albeit at much lower levels than in melanoma (15). This evidence concerns the gene PMEL and melanoma.